Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GANX 
Gain Therapeutics Inc (GANX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: GANX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.33
1 Year Target Price $8.33
| 3 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.1% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 73.34M USD | Price to earnings Ratio - | 1Y Target Price 8.33 |
Price to earnings Ratio - | 1Y Target Price 8.33 | ||
Volume (30-day avg) 7 | Beta 0.12 | 52 Weeks Range 1.41 - 3.19 | Updated Date 10/15/2025 |
52 Weeks Range 1.41 - 3.19 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -74.33% | Return on Equity (TTM) -240.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 60850909 | Price to Sales(TTM) 255.5 |
Enterprise Value 60850909 | Price to Sales(TTM) 255.5 | ||
Enterprise Value to Revenue 138.33 | Enterprise Value to EBITDA -1.55 | Shares Outstanding 35948606 | Shares Floating 34610239 |
Shares Outstanding 35948606 | Shares Floating 34610239 | ||
Percent Insiders 3.64 | Percent Institutions 10.56 |
Upturn AI SWOT
Gain Therapeutics Inc
Company Overview
History and Background
Gain Therapeutics was founded in 2017 and is focused on developing structurally targeted allosteric regulators (STARs) to treat genetically defined diseases. They target misfolded proteins to restore enzyme activity and cellular function.
Core Business Areas
- Drug Discovery and Development: Developing STARs molecules for lysosomal storage disorders (LSDs) and central nervous system (CNS) diseases.
Leadership and Structure
Khaled Daoud as CEO. The structure is typical of a clinical-stage biotech company, with teams focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- GT-02287 (GBA1 Parkinson's Disease): A STAR molecule targeting GBA1 misfolding in Parkinson's Disease. This drug is in phase 1. Competitors include Denali Therapeutics and Prevail Therapeutics (acquired by Eli Lilly).
- GT-02329 (GCase Deficiency related to neuronopathic Gaucher disease (nGD)): A STAR molecule for neuronopathic Gaucher disease (nGD). GT-02329 has demonstrated robust blood-brain barrier penetration and is currently in pre-clinical development. Key competitors include Sanofi Genzyme, Idorsia.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. The market for treatments for lysosomal storage disorders (LSDs) is expanding, driven by increased awareness and improved diagnostic tools.
Positioning
Gain Therapeutics is positioned as an innovator in the field of allosteric drug discovery, specifically targeting protein misfolding in genetic diseases. Their advantage lies in their STARs platform.
Total Addressable Market (TAM)
The total addressable market for LSD and neurodegenerative disease therapies is substantial. Estimates vary widely depending on the specific indication, but the total market is in the tens of billions of dollars. Gain Therapeutics is positioned to capture a portion of this market with successful development and commercialization of its STARs molecules.
Upturn SWOT Analysis
Strengths
- Novel STARs technology platform
- Targeting unmet medical needs in genetic diseases
- Strong intellectual property position
Weaknesses
- Limited financial resources as a clinical-stage company
- High risk of clinical trial failure
- Reliance on successful development of pipeline candidates
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of STARs platform to new disease targets
- Positive clinical trial results driving investor confidence
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Failure to secure adequate funding
Competitors and Market Share
Key Competitors
- SNY
- LLY
- VRDN
Competitive Landscape
Gain Therapeutics competes with larger pharmaceutical companies and other biotech firms in the LSD and neurodegenerative disease space. Their STARs platform offers a differentiated approach but requires successful clinical validation.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of the drug pipeline and advancement of clinical trials.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization of products. Analyst estimates vary widely based on these factors.
Recent Initiatives: Advancing clinical trials for GT-02287, progressing pre-clinical development of GT-02329, and exploring new targets for the STARs platform.
Summary
Gain Therapeutics is a clinical-stage biotech company with a novel drug discovery platform. Its strength lies in the STARs technology and pipeline targeting unmet medical needs. Challenges include financial constraints and the high risk of clinical trial failure. Successful clinical trial outcomes and strategic partnerships are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a financial professional. Market share data is an estimate and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gain Therapeutics Inc
Exchange NASDAQ | Headquaters Bethesda, MD, United States | ||
IPO Launch date 2021-03-18 | President, CEO & Director Mr. Gene Mack M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://gaintherapeutics.com |
Full time employees 23 | Website https://gaintherapeutics.com | ||
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.